PARP1 and cancer: The observation that the use of ABT-888 and olaparib, two well-known PARP-inhibitors, improved the efficacy of chemotherapeutics on cancer cells carrying SNP rs1805407 suggests that this variant is associated with higher PARP-1 expression and supports the idea of potential synergism between conventional therapeutics and pharmacologic PARP inhibition in the treatment of melanoma.